Sigma-Aldrich Q3 Revenues up 4 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported a 4 percent increase in its third quarter revenues, as the company beat the consensus Wall Street estimate on the top line but missed on the bottom line.

For the three months ended Sept. 30, Sigma-Aldrich took in $664 million in revenues, up from $639 a year ago, and edging out the average analyst estimate of $661.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.